Drug Trial Radar · NCT03155620
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,377
Actual
Start
Jul 31, 2017
Primary completion
Mar 31, 2025
Study completion Jan 6, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- May 16, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Conditions
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Histiocytic Sarcoma
- Juvenile Xanthogranuloma
- Langerhans Cell Histiocytosis
- Malignant Glioma
- Recurrent Childhood Rhabdomyosarcoma
- Recurrent Ependymoma
- Recurrent Ewing Sarcoma
- Recurrent Glioma
- Recurrent Hepatoblastoma
- Recurrent Langerhans Cell Histiocytosis
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Medulloblastoma
- Recurrent Neuroblastoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Primary Central Nervous System Neoplasm
- Recurrent Rhabdoid Tumor
- Recurrent Soft Tissue Sarcoma
- Refractory Ewing Sarcoma
- Refractory Glioma
- Refractory Hepatoblastoma
- Refractory Langerhans Cell Histiocytosis
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Solid Neoplasm
- Refractory Medulloblastoma
- Refractory Neuroblastoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Primary Central Nervous System Neoplasm
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Rhabdoid Tumor
- Stage III Osteosarcoma AJCC v7
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Osteosarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Stage IVA Osteosarcoma AJCC v7
- Stage IVB Osteosarcoma AJCC v7
- Wilms Tumor
Interventions
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow Aspiration and BiopsyProcedure
Undergo a bone marrow and/or biopsy
Bone ScanProcedure
Undergo a bone scan
Computed TomographyProcedure
Undergo CT, PET/Ct, and/or CT/MRI
EnsartinibDrug
Given PO
ErdafitinibDrug
Given PO
IvosidenibDrug
Given PO
Laboratory Biomarker AnalysisOther
Undergo molecular analysis
Larotrectinib SulfateDrug
Given PO or via nasogastric- or gastric-tube
Magnetic Resonance ImagingProcedure
Undergo MRI, PET/MRI, and/or CT/MRI
Mutation Carrier ScreeningProcedure
Undergo tumor tissue mutation screening
OlaparibDrug
Given PO
PalbociclibDrug
Given PO
Pharmacological StudyOther
Correlative studies
Positron Emission TomographyProcedure
Undergo PET, PET/CT, and/or PET/MRI
Radionuclide ImagingProcedure
Undergo radionuclide imaging
SamotolisibDrug
Given PO
SelpercatinibDrug
Given PO
Selumetinib SulfateDrug
Given PO
TazemetostatDrug
Given PO
TipifarnibDrug
Given PO or via nasogastric or gastric tube
UlixertinibDrug
Receive PO
VemurafenibDrug
Given PO
X-Ray ImagingProcedure
Undergo an x-ray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer DrugsTime frame: Up to 2 years from study entry
Locations
172 sites in 4 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Banner Children's at Desert
Mesa, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
Naval Medical Center -San Diego
San Diego, California
UCSF Medical Center-Mission Bay
San Francisco, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
Nicklaus Children's Hospital
Miami, Florida
AdventHealth Orlando
Orlando, Florida
Arnold Palmer Hospital for Children
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Showing 40 of 172 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.